By Mr. Abhay Ray 
Introduction to Cipla Limited
Cipla Limited is an Indian multinational pharmaceutical company. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions.Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, their guiding purpose. Driven by the same purpose, they have extended their presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, they are deepening their presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.
Incorporation
Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. In July 1984, the name of the company was changed to ‘Cipla’
Mission and Vision
The mission of Cipla is to be the top global healthcare provider, utilising innovation and technology to cater to all patients’ basic needs.
The mission and vision of the company as said by Dr.Y K Hamied, Chairman Cipla, is not just making medicines. It is about making a difference.
Founder Details of Cipla
Dr. Khwaja Abdul Hamied (31 October 1898 – 23 June 1972) was an Indian industrial and pharmaceutical chemist, founded Cipla Limited in 1935. Dr. Hamied was a scientist who opposed imperialism and was a nationalist and freedom fighter in India.
- A. Hamied Education
After matriculating from Islamia High School, Etawah, Hamied completed his Intermediate in Science from Agra College in 1917. Having decided to become a chemist, he then spent a year at a Madras trade school studying leather technology before enrolling at Muir Central College in Allahabad, from which he completed his B.Sc. in chemistry in 1920, and graduated from Allahabad University in Allahabad, Uttar Pradesh and held M.A. and PhD degrees from the Humboldt University of Berlin in Germany.
- A. Hamied Career
Apart from conceiving the idea of establishing a National Chemical Laboratory and making it a reality, Dr Khwaja Hamied floated the idea and conceptualized the establishment of the Council of Scientific and Industrial Research (CSIR)as an umbrella organization to run a clutch of laboratories. Dr. Hamied was an honorary professor and a member of the executive council of the Aligarh Muslim University, member of the Senate of Bombay University and a fellow of the Royal Institute of Chemistry, UK. He was also a member of the Bombay Legislative Council from 1937 to 1962, refusing the offer of becoming a Muslim Minister in the cabinet in Bombay, Hamied also served as Sheriff of Bombay. Dr Khwaja Abdul Hamied died in 1972 after a brief illness
Cipla – Product and Services
Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including the anti-depressant escitalopram oxalate, lamivudine, and fluticasone propionate. Cipla is the world’s largest manufacturer of antiretroviral drugs.
In July 2020, the company announced the introduction of Gilead Sciences’ Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and DCGI approval for “restricted emergency use” in COVID-19 treatment of patients in critical condition.
Dividend of Cipla
| Announcement Date | Ex-Dividend Date | Dividend Type |
Dividend (₹) |
|
10 May, 2024 |
02 Aug, 2024 | Final |
13.00 |
|
12 May, 2023 |
21 Jul, 2023 | Final |
8.50 |
|
27 Jul, 2022 |
08 Aug, 2022 | Final |
5.00 |
|
14 May, 2021 |
09 Aug, 2021 | Final |
5.00 |
|
20 Feb, 2020 |
19 Mar, 2020 | Interim |
3.00 |
|
21 Feb, 2020 |
19 Mar, 2020 | Special | 1.00 |
| 22 May, 2019 | 31 Jul, 2019 | Final |
3.00 |
|
22 May, 2018 |
13 Aug, 2018 | Final | 3.00 |
| 25 May, 2017 | 26 Jul, 2017 | Final |
2.00 |
|
24 May, 2016 |
12 Sep, 2016 | Final |
2.00 |
Bonus of Cipla
|
Announcement Date |
Ex-Bonus Date | Bonus Ratio |
| 11 Feb, 2006 | 24 Apr, 2006 |
3:2 |
|
07 Oct, 1999 |
18 Oct, 1999 | 2:1 |
| 24 Mar, 1994 | 04 Apr, 1994 |
5:1 |
|
30 Sep, 1992 |
06 Oct, 1992 | 1:1 |
Split of Cipla
|
Announcement Date |
Ex-Split Date | Old FV | New FV |
| 23 Mar, 2004 | 11 May, 2004 | 10 |
2 |
|
29 Jul, 1994 |
29 Jul, 1994 | 100 |
10 |
|
Stock rate |
Face value | Book value | Beta value | Market cap. | TTM EPS | Sector PE |
| 1,507.70(as on 10, Dec 2024) |
2
|
330.68 | 0.30 | 1,21,763 | 55.41 |
48.67 |
Cipla – Mergers and Acquisitions
Cipla has acquired six organizations. Their most recent acquisition was Mirren Pty Ltd. for $33 million on July 12, 2018. The other acquisitions are:
|
Acquiree name |
Date of acquisition |
Amount |
|
Mirren Pty Ltd. |
July 12, 2018 |
$33 million |
|
Exelan Pharmaceuticals |
September 4, 2015 |
$50 million |
|
InvaGen Pharmaceuticals |
September 4, 2015 |
$500 million |
|
Quality Chemicals Ltd. |
May 25, 2015 |
$30 million |
|
Cipla Medpro South Africa Ltd. |
July 16, 2013 |
$512 million |
|
Meditab Specialities |
Nov 23, 2011 |
$16.7 million |
Cipla – Investments
As of 2022, Cipla has made four investments. Their most recent investment was on June 28, 2022, when GoApptiv raised ₹260 million. The other investments are:
|
Date of Announcement |
Company name | Funding round |
Money raised |
|
June 28, 2022 |
GoApptiv | Corporate Round |
₹260 million |
|
Jun 10, 2020 |
GoApptiv | Corporate Round |
$1.2 million |
|
Feb 18, 2019 |
Wellthy Therapeutics | Corporate Round |
$1.5 million |
|
May 12 ,2014 |
Chase Pharmaceuticals | Series B |
$21 MILLION |
Growth and Revenue of Cipla
The consolidated revenue of Cipla Limited for fiscal year 2024 was over 257 billion Indian rupees. This was a significant increase from the revenue in 2022 which stood at approximately 217 billion rupees.The revenues of Cipla stood at ₹ 232,653 m in FY23, which was up 5.3% compared to ₹ 220,851 m reported in FY22. CIPLA’s revenue has grown from ₹ 168,390 m in FY19 to ₹ 232,653 m in FY23. Over the past 5 years, the revenue of CIPLA has grown at a CAGR of 8.4%.
Awards and Recognitions of Cipla
Cipla received Economic Times Family Business Award, and won the 4th India Logistics and Warehousing Excellence Awards 2022. BW Business world featured Cipla amongst the Top 40 BW Most Sustainable Companies in India. Cipla scores highest among pharma companies in CRISIL’s Sustainability Rating 2022.Cipla bags the first prize in the GOQii Corporate Challenge at an organisational level, and recognised at the 35th Goa Statehood Day for contributing significantly to healthcare in the state of Goa. ET Brand Equity Kaleido Awards 2022.Cipla receives the India Pharma Leader of the Year Award. Cipla receives US-INDIA Trade Award – “Pharma & Healthcare” Category. Cipla was recognised as an Industry Mover in the S&P Global Sustainability Yearbook 2022.
Top Competitors of Cipla
- Sun Pharma
- Torrent Pharma
- Devi’s Labortories
- Reddy’s Laboratories
- Pfizer
- Mankind
Conclusion
Cipla continues to be a leading global pharmaceutical company, recognized for its commitment to accessible healthcare and innovative solutions. With a strong portfolio across respiratory, oncology, and cardiovascular therapies, the company has made significant strides in expanding its presence in emerging markets and advancing in biosimilars and complex generics. Cipla’s focus on sustainability and digital transformation further positions it as a forward-thinking industry leader, poised for continued growth and impact in the healthcare sector.Cipla Ltd. stands as a pharmaceutical giant with a robust foundation, consistent financial growth, and a clear vision for the future. Its focus on R&D, digital initiatives, and renewable energy, combined with a strategic push into diagnostics and advanced therapies, sets Cipla apart as an innovative leader in the industry..
GetMyIndia.com RaysVeda.com GetMyStartup.com LawCanal.com ABHAYRAY.COM ZinCob.com